Poseida Therapeutics Inc PSTX

$9.50 -0.06 (-0.63%)

Valuation

Market cap: 928,853,000
Revenue TTM: $64,700,000
Net income TTM: $-123,430,000
PE ratio: 0.00
Forward PE: —
Profit margin: -190.77%
Debt to equity: 0.68

Trading

Volume: 21,420,600
Avg volume: 1,996,096
Day's range: $9.49 – $9.67
Shares out: 97,774,000
Stochastic %K: 45%
Beta: 1.63
Analysts: Hold
Price target: $10.33

Price

Latest news

Jul 23, 2025, 9:00 AM EDT · 1 year ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

Jan 8, 2025, 1:35 AM EST · 1 year ago

Roche to complete acquisition of U.S. biopharma company Poseida

Dec 9, 2024, 12:00 PM EST · 1 year ago

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 27, 2024, 6:14 PM EST · 1 year ago

POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX

Nov 26, 2024, 1:17 PM EST · 1 year ago

Poseida shares triple on Tuesday, boosted by Roche collaboration

Nov 26, 2024, 11:10 AM EST · 1 year ago

Why This Gene-Therapy Company's Stock Is Rising 228%

Nov 26, 2024, 1:29 AM EST · 1 year ago

Roche to acquire US-based Poseida Therapeutics

Nov 26, 2024, 1:10 AM EST · 1 year ago

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Nov 26, 2024, 1:10 AM EST · 1 year ago

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

Nov 14, 2024, 9:00 AM EST · 1 year ago

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Nov 11, 2024, 4:05 PM EST · 1 year ago

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Nov 7, 2024, 4:05 PM EST · 1 year ago

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Nov 5, 2024, 4:05 PM EST · 1 year ago

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Oct 24, 2024, 8:00 AM EDT · 1 year ago

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

Oct 17, 2024, 8:00 AM EDT · 1 year ago

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

Oct 3, 2024, 4:30 PM EDT · 2 years ago

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

Sep 27, 2024, 4:30 PM EDT · 2 years ago

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

Sep 16, 2024, 8:00 AM EDT · 2 years ago

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Sep 5, 2024, 9:00 AM EDT · 2 years ago

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Sep 4, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Aug 29, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics to Present at Upcoming Investor Conferences

Aug 5, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024

Jul 1, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum

Jun 3, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

May 14, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

May 9, 2024, 9:00 AM EDT · 2 years ago

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

May 1, 2024, 9:30 PM EDT · 2 years ago

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Apr 18, 2024, 8:00 AM EDT · 2 years ago

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 17, 2024, 9:00 AM EDT · 2 years ago

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus

Apr 8, 2024, 12:00 PM EDT · 2 years ago

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

Apr 1, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Mar 19, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 13, 2024, 4:05 PM EDT · 2 years ago

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

Mar 7, 2024, 4:07 PM EST · 2 years ago

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

Jan 4, 2024, 8:00 AM EST · 2 years ago

Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones

Dec 10, 2023, 12:00 PM EST · 2 years ago

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 9, 2023, 4:05 PM EST · 2 years ago

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023

Nov 2, 2023, 9:01 AM EDT · 2 years ago

Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition

Oct 9, 2023, 4:30 PM EDT · 3 years ago

Poseida Therapeutics Announces Leadership Transition

Aug 8, 2023, 4:05 PM EDT · 3 years ago

Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

Aug 7, 2023, 9:01 AM EDT · 3 years ago

Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update

Aug 7, 2023, 9:00 AM EDT · 3 years ago

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Jul 5, 2023, 8:00 AM EDT · 3 years ago

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies

Jun 26, 2023, 8:00 AM EDT · 3 years ago

Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes

Jun 1, 2023, 8:00 AM EDT · 3 years ago

Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders

May 23, 2023, 8:00 AM EDT · 3 years ago

Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day

May 22, 2023, 8:00 AM EDT · 3 years ago

Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis